BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26101290)

  • 1. New psychoactive substances: catalysing a shift in forensic science practice?
    Tettey J; Crean C
    Philos Trans R Soc Lond B Biol Sci; 2015 Aug; 370(1674):. PubMed ID: 26101290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The comprehensive investigation of the new psychoactive substances].
    Andreev AI; Malkova TL; Apushkin DY; Bulatov IP; Mashchenko PS
    Sud Med Ekspert; 2016; 59(2):55-58. PubMed ID: 27070039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Advances and Future Developments in Forensic Toxicology: From Standard Practices to New Psychoactive Substances.
    Busardo FP; Pichini S; Peters FT
    Curr Pharm Des; 2017; 23(36):5427-5428. PubMed ID: 29237370
    [No Abstract]   [Full Text] [Related]  

  • 4. Investigating the appearance of new psychoactive substances in South Australia using wastewater and forensic data.
    Bade R; Stockham P; Painter B; Celma A; Bijlsma L; Hernandez F; White JM; Gerber C
    Drug Test Anal; 2019 Feb; 11(2):250-256. PubMed ID: 30129282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug policy and global regulatory capitalism: the case of new psychoactive substances (NPS).
    Seddon T
    Int J Drug Policy; 2014 Sep; 25(5):1019-24. PubMed ID: 24768473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of Novel Psychoactive Substances in Postmortem Matrices by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS).
    Fagiola M; Hahn T; Avella J
    J Anal Toxicol; 2018 Oct; 42(8):562-569. PubMed ID: 30371846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New psychoactive substances: An actual problem or an overestimated phenomenon?
    Vaiano F; Pascali JP; Bertol E
    Forensic Sci Int; 2019 Nov; 304():109941. PubMed ID: 31574421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicology in international drug control-Prioritizing the most harmful, persistent and prevalent substances.
    Ifeagwu SC; Raithelhuber M; Crean C; Gerostamoulos D; Chung H; Tettey JN
    Forensic Sci Int; 2017 May; 274():2-6. PubMed ID: 27899215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
    Grafinger KE; Bernhard W; Weinmann W
    Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of updatable analytical screening methods for new psychoactive substances in clinical and forensic toxicology.
    Berardinelli D; Berretta P; Umani Ronchi F; Di Trana A
    Clin Ter; 2022; 173(4):304-305. PubMed ID: 35857046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M; Wilkins C
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seized drug reporting of NPS helps to guide regional toxicological practice: A 17 month review between 2022 and 2023.
    Ellefsen KN; Papsun DM; Mata DC; Ayala JL; Modell C; Goodson LJ; Truver MT
    J Forensic Sci; 2024 Jul; 69(4):1392-1399. PubMed ID: 38853356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive analytical process, from NPS threat identification to systematic screening: Method validation and one-year prevalence study.
    Garneau B; Desharnais B; Laquerre J; Côté C; Taillon MP; Martin PY; Daigneault G; Mireault P; Lajeunesse A
    Forensic Sci Int; 2021 Jan; 318():110595. PubMed ID: 33279767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a rapid LC-MS/MS method for the detection of 182 novel psychoactive substances in whole blood.
    Giorgetti A; Barone R; Pelletti G; Garagnani M; Pascali J; Haschimi B; Auwärter V
    Drug Test Anal; 2022 Feb; 14(2):202-223. PubMed ID: 34599648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory approaches to new psychoactive substances (NPS) in the European Union.
    Hughes B; Griffiths P
    Addiction; 2014 Oct; 109(10):1591-3. PubMed ID: 25163707
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioanalytical Methods for New Psychoactive Substances.
    Wagmann L; Maurer HH
    Handb Exp Pharmacol; 2018; 252():413-439. PubMed ID: 29374833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel screening method for 64 new psychoactive substances and 5 amphetamines in blood by LC-MS/MS and application to real cases.
    Vaiano F; Busardò FP; Palumbo D; Kyriakou C; Fioravanti A; Catalani V; Mari F; Bertol E
    J Pharm Biomed Anal; 2016 Sep; 129():441-449. PubMed ID: 27490334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence, Diversity, and Control of New Psychoactive Substances: A Global Perspective.
    Tettey JNA; Crean C; Ifeagwu SC; Raithelhuber M
    Handb Exp Pharmacol; 2018; 252():51-67. PubMed ID: 29896655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial on "New challenges and innovation in forensic toxicology: focus on the 'New Psychoactive Substances'" by Donata Favretto, Jennifer P. Pascali and Franco Tagliaro.
    Fanali S
    J Chromatogr A; 2013 Apr; 1287():83. PubMed ID: 23394944
    [No Abstract]   [Full Text] [Related]  

  • 20. New drug controls and reduced hospital presentations due to novel psychoactive substances in Edinburgh.
    Pettie J; Burt A; Knipe DW; Torrance H; Dow M; Osinski K; Greig R; Sabatini D; Easterford K; Dear J; Eddleston M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2303-2310. PubMed ID: 29911343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.